Skip to main content

Immunology

Can I get the INFLUENZA and COVID Vaccines together? The CDC says: "YES...both vaccines can be given at the same visit, people should follow the recommended schedule for either vaccine.... ideally get a flu vaccine by the end of October." https://t.co/T49zm6Cxyc

Dr. John Cush @RheumNow( View Tweet )

Sep 27, 2021
New study on #COVID19Vaccine in autoimmune cytopenias 🩸7.4% had clinically significant ⬇️ in counts 🩸 All successfully managed w/steroids & transfusion 🩸 Mild ⬇️ in 10% AIHA and 20% ITP ⭐️Vaccination safe with close monitoring⭐️ https://t.co/qGZe6LiPKz

AmericanJournalofHematology @AjHematology( View Tweet )

Sep 26, 2021
Prospective study of 77 RA patients in remission --> vax w/ BNT162b2 (BioNTech-Pfizer) (w/ temp D/C of DMARDs per ACR) found a vaccine-related flare rate of 7/8% (6 pts) w/ 5/6 flares after 2nd dose (2.6 days), resolved w/in 2 wks https://t.co/YOL3YVS2ne

Dr. John Cush @RheumNow( View Tweet )

Sep 22, 2021

Lymphoma in RA: Disease Activity Matters

MedPage Today
Sep 08, 2021

Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.

In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for

Read Article
Strept pneumoniae vaccinations are underutilized. A Univ of Pittsburgh project utilized EMR reminders to prompt vax w/ Prevnar/PCV13 & Pneumovax/PPSV23. PPSV23 vax increased 28% to 62% and either PPSV23, PCV13 incr 50% to 77% using EMR https://t.co/DO9WnyBHI1

Dr. John Cush @RheumNow( View Tweet )

Sep 07, 2021

Not All Immunosuppression Alters Vaccine Immunogenicity

Sep 02, 2021

Chronic inflammatory disease (CID) patients are urged to receive the COVID-19 vaccines; but when a cohort of CID patients treated with immunosuppressive medications were given an mRNA-based SARS-CoV-2 vaccination, only those treated with glucocorticoids and B cell depleting therapies (BCDT)

Read Article

TNF Inhibitor Induced IgA Vasculitis in IBD

Aug 31, 2021

A new descriptive series shows an uncommon association between IgA vasculitis (IgAV) and inflammatory bowel diseases (IBD), with most cases interestingly arising after  or during anti-TNF-α therapy.



A retrospectively analysis of the GETAID and FVSG networks identified, 43 patients

Read Article
Octave study examined COVID-19 Vax Ab responses in 600 immunocompromised-IMC (Cancer, IMID) pts. Compared to normals, fewer IMC seroconverted @4 wks (89 vs 100%). 40% of IMC had a low Ab resp; 11% of IMC had zero Ab response https://t.co/11VkeNKzvL

Dr. John Cush @RheumNow( View Tweet )

Aug 31, 2021
2021–22 influenza season coincides with continued COVID infx & Sxs may be confused betw both. ACIP Influenza vaccination guidelines: 1. Annual flu vaccine rec to all >6mos; 2. COVID Vax can be given w/ Flu Vax; 3. give before Nov 2021 https://t.co/oIkl50GI0W

Dr. John Cush @RheumNow( View Tweet )

Aug 26, 2021

ACR Guidance on Timing of 3rd Dose Booster with Immunomodulatory Drugs

ACR Press Release
Aug 25, 2021

The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases following recent recommendations from the CDC that certain immunocompromised patients receive a third dose of an available mRNA

Read Article

The Predictive Value of Morning Stiffness

Aug 25, 2021

A prospective study evaluated the value and associations with morning stiffness in patients with clinically suspect arthralgia, and found that the presence of morning stiffness increases the odds of inflammation (as detected by CRP and MRI synovitis).

Read Article

Rheumatic Events With Checkpoint Inhibitors: Tumor Type Matters

MedPage Today
Aug 24, 2021

Among the factors that were associated with an increased risk for the development of rheumatic immune-related adverse events following cancer treatment with immune checkpoint inhibitors (ICIs) was the type of malignancy involved, a large case-control study found.

Read Article

FDA Approves First COVID-19 Vaccine

Aug 23, 2021

Today, the U.S. Food and Drug Administration (FDA) approved the first COVID-19 vaccine, manufactured by Pfizer-BioNTech COVID-19 the vaccine, now marketed as Comirnaty (koe-mir’-na-tee), is approved for the prevention of COVID-19 disease in individuals 16 years of age and older.



This

Read Article
FDA has expanded the use of SHINGRIX vaccine to include adults 18 years and older who are compromised by immunodeficiency or immunosuppression caused by disease or therapy. https://t.co/Wf2mzvOQcU

Dr. John Cush @RheumNow( View Tweet )

Aug 13, 2021

Anakinra's Effects on COVID-19 Outcomes

Aug 12, 2021

Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially highly elevated ferritin and C-reactive

Read Article

COVID Vaccine Booster Effective for Transplant Recipients in Small Trial

MedPage Today
Aug 11, 2021

For organ transplant recipients, a third dose of Moderna's COVID-19 vaccine more than tripled the proportion with a sufficient antibody response, a randomized trial showed.



A third dose 2 months after the regular two-shot series produced a serologic response previously shown to confer

Read Article

Rare Risk of Serious Adverse Events After COVID Vaccination

CDC/MMWR
Aug 10, 2021

The CDC had reported the Advisory Committee on Immunization Practices (ACIP) study of rare serious adverse events after COVID-19 vaccination and assert that the excessive morbidity and mortality from COVID-19 (and the protection afforded by vaccination) far exceeds the risk of rare safety

Read Article

FDA Approves Anifrolumab in SLE

Aug 02, 2021

AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.  



Saphnelo the 

Read Article

DMARD Effects on COVID-19 Outcomes

Jul 26, 2021

Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (

Read Article

Rare Myocarditis Risk following COVID-19 Vaccine

CDC/MMWR
Jul 12, 2021

MMWR review of the risk of myocarditis and pericarditis reports a June 23, 2021 recommendation by the Advisory Committee on Immunization Practices that the benefits of COVID-19 vaccination clearly outweighed the risks of myocarditis after vaccination. 



The COVID-19 vaccines from 

Read Article

ICYMI: 2020 Rheumatology Year in Review

Jul 08, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article
CDC: as of 5/15/2021; the rates of flu test positivity was 0.051-0.18% for the 2020-21 flu season - compared to usual rate of 10%-19% before COVID. Actual influenza hospitalizations dropped from 44.2 to 0.8/100 000 population https://t.co/N8b1sQWWIh

Dr. John Cush @RheumNow( View Tweet )

Jul 01, 2021

The Potential of Rituximab Efficacy in Systemic Sclerosis

Jun 28, 2021

Rituximab (RTX) has been in the news a lot lately; more surprisingly for its potential benefits in progressive systemic sclerosis (SSc).

Ebata and colleagues have published the results of a double-blind, randomised, placebo-controlled trial comparing intravenous RTX to placebo in 56 SSc

Read Article
#EULAR2021 LB0002 #COVID vax safety in RMD ⭐️78% received Pfizer, 16% Astra Zeneca ⭐️5% of pts flares, 1.2% severe flares ⭐️31% had vax side effects, 0.1% severe AEs Side effect profile similar to gen population. Good data for uncertain patients! @RheumNow @rheum_covid https://t.co/PGZcph9Mu6
Eric Dein @ejdein1( View Tweet )
Jun 05, 2021
#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg
Dr. John Cush @RheumNow( View Tweet )
Jun 05, 2021
×